Comparative Atomistic Insights on Apo and ATP-I1171N/S/T in Nonsmall-Cell Lung Cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative Atomistic Insights on Apo and ATP-I1171N/S/T in Nonsmall-Cell Lung Cancer
Authors
Keywords
-
Journal
ACS Omega
Volume -, Issue -, Pages -
Publisher
American Chemical Society (ACS)
Online
2023-11-07
DOI
10.1021/acsomega.3c05785
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of compound mutations I1171N + F1174I and I1171N + L1198H on the structure of ALK in NSCLC pathogenesis: atomistic insights
- (2022) Elliasu Y. Salifu et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- ATP–Magnesium Coordination: Protein Structure-Based Force Field Evaluation and Corrections
- (2021) Floris P. Buelens et al. Journal of Chemical Theory and Computation
- Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
- (2021) Hayato Mizuta et al. Nature Communications
- Additive CHARMM36 Force Field for Nonstandard Amino Acids
- (2021) Anastasia Croitoru et al. Journal of Chemical Theory and Computation
- Molecular Dockings and Molecular Dynamics Simulations Reveal the Potency of Different Inhibitors against Xanthine Oxidase
- (2021) Yue Pan et al. ACS Omega
- Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature
- (2021) Bart Koopman et al. Clinical Lung Cancer
- Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma—A Comprehensive Update
- (2021) Annette K. Brenner et al. Pharmaceutics
- gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS
- (2021) Mario S. Valdés-Tresanco et al. Journal of Chemical Theory and Computation
- The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
- (2021) Yue Pan et al. Frontiers in Oncology
- Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase
- (2021) Shuai Liang et al. Frontiers in Cell and Developmental Biology
- Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer
- (2020) Ken Takahashi et al. Thoracic Cancer
- UniProt: the universal protein knowledgebase in 2021
- (2020) et al. NUCLEIC ACIDS RESEARCH
- Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
- (2019) Muhammad Wasi Alam et al. Frontiers in Oncology
- Conformational Transition of Key Structural Features Involved in Activation of ALK Induced by Two Neuroblastoma Mutations and ATP Binding: Insight from Accelerated Molecular Dynamics Simulations
- (2018) Mu-Yang He et al. ACS Chemical Neuroscience
- A molecular dynamics investigation into the mechanisms of alectinib resistance of three ALK mutants
- (2018) Muyang He et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Activity of brigatinib in the setting of alectinib resistance mediated by ALK -I1171S in ALK rearranged lung cancer
- (2018) Kartik Sehgal et al. Journal of Thoracic Oncology
- Mechanisms of receptor tyrosine kinase activation in cancer
- (2018) Zhenfang Du et al. Molecular Cancer
- Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
- (2018) Satoshi Yoda et al. Cancer Discovery
- Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
- (2018) Geeta Sharma et al. Cancers
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling
- (2017) Jianzhong Chen et al. PHYSICAL CHEMISTRY CHEMICAL PHYSICS
- The role of the ALK receptor in cancer biology
- (2016) B. Hallberg et al. ANNALS OF ONCOLOGY
- Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer
- (2015) Zhong Ni et al. JOURNAL OF MOLECULAR MODELING
- Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non–small-cell Lung Cancer Exhibiting Resistance to Ceritinib
- (2015) Gouji Toyokawa et al. Journal of Thoracic Oncology
- I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib
- (2015) Sai-Hong Ignatius Ou et al. LUNG CANCER
- PubChem Substance and Compound databases
- (2015) Sunghwan Kim et al. NUCLEIC ACIDS RESEARCH
- The Mechanism of ATP-Dependent Allosteric Protection of Akt Kinase Phosphorylation
- (2015) Shaoyong Lu et al. STRUCTURE
- A dynamically coupled allosteric network underlies binding cooperativity in Src kinase
- (2015) Zachariah H. Foda et al. Nature Communications
- Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review
- (2014) Eugen F Mesaros et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib
- (2014) Gouji Toyokawa et al. Journal of Thoracic Oncology
- How does conformational flexibility influence key structural features involved in activation of anaplastic lymphoma kinase?
- (2014) Tatyana G. Karabencheva et al. Molecular BioSystems
- Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
- (2013) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploring the ATP-binding site of P2X receptors
- (2013) Thierry Chataigneau et al. Frontiers in Cellular Neuroscience
- Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies
- (2011) Sandrine Medves et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Open Babel: An open chemical toolbox
- (2011) Noel M O'Boyle et al. Journal of Cheminformatics
- Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
- (2010) Christian C. Lee et al. BIOCHEMICAL JOURNAL
- Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
- (2010) Roberto T. Bossi et al. BIOCHEMISTRY
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic lymphoma kinase: signalling in development and disease
- (2009) Ruth H. Palmer et al. BIOCHEMICAL JOURNAL
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading
- (2009) Oleg Trott et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
- (2009) Garrett M. Morris et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
- Kinase mutations in human disease: interpreting genotype–phenotype relationships
- (2009) Piya Lahiry et al. NATURE REVIEWS GENETICS
- Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
- (2008) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- Construction of the free energy landscape of biomolecules via dihedral angle principal component analysis
- (2008) Alexandros Altis et al. JOURNAL OF CHEMICAL PHYSICS
- CHARMM-GUI: A web-based graphical user interface for CHARMM
- (2008) Sunhwan Jo et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
- (2008) Kentaro Inamura et al. Journal of Thoracic Oncology
- Structural and biochemical characterization of the KRLB region in insulin receptor substrate-2
- (2008) Jinhua Wu et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now